Based on the above research results, it is possible to explore the development of specific inhibitors targeting SRSF7 or PKM2 as novel HCC therapeutic drugs for combined use with other known anticancer drugs to improve treatment efficacy and reduce side effects. The gene discussed is PKM; the disease is hepatocellular carcinoma.